FY27 Biologics and Formulation Growth
Management expects biologics and formulation business to be the primary contributors to growth in FY27, while API will grow at a steady pace.
SHILPAMED / guidance tracker
Keep management guidance in view.
Shilpa Medicare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
Nor UDCA Q4 Revenue Visibility
Strong order book already in place for Q4 FY26 from all three marketing partners plus captive sales, indicating revenue acceleration earlier than expected.
API Volume Ramp-up Timeline
Volume ramp-up from recently expanded API capacity expected to commence from Q2 FY27, providing growth visibility for the API segment.
Albumin India Commercialization Target
If clinical studies progress as planned, Albumin could be commercialized in India by end FY27 or early FY28.